Skip to content
Taxonomy
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Read More
CMT-SORD: Share Your Story
CMT-SORD: What is Your Story? For many with CMT, the Read More
CMTA Announces New Center of Excellence in Thailand
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
CMTA Appoints David Skarinsky to its Therapy Expert Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
The Charcot-Marie-Tooth Association (CMTA) is excited to share that our Read More
CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT
Finding Your Gene Researchers have discovered over 120 genes linked Read More
TAKE ACTION! Sign the Petition to Accelerate CMT-SORD
What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, Read More
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication Read More
